MDPI AG
The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials
Type 2 Diabetes Mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD) are part of metabolic syndrome and share multiple causal associations. Both conditions have an alarmingly increasing incidence and lead to multiple complications, which have an impact on a variety of organs and systems, such as the kidneys, eyes, and nervous and cardiovascular systems, or may cause metabolic disruptions. Sodium-glucose cotransporter 2-inhibitors (SGLT2-i), as an antidiabetic class with well-established...
Preuzmite dokument
2023
Roxana Adriana Stoica
,
Anca Pantea Stoian
,
Manfredi Rizzo
,
Andrej Janež
,
Špela Volčanšek
,
Djordje Popovic
,
Emir Muzurović
,
Teodor Salmen
,
Ioana-Cristina Bica
Bentham Science Publishers Ltd.
Non-alcoholic Fatty Liver Disease in Children
Abstract:
Non-alcoholic fatty liver disease (NAFLD) has become the most common liver disease in the
paediatric age. The growing prevalence of NAFLD and its advanced phenotype, non-alcoholic steatohepatitis
(NASH), in children and adolescents parallels similar trends in obesity and type 2 diabetes
mellitus. This trend may have serious long-term implications, including hepatic and extra-hepatic morbidity
and mortality, the latter being related mostly due to cardiovascular disease and malignancies....
Preuzmite dokument
2023
Nataša Kadić
,
Christos S. Mantzoros
,
Dušanka Novosel
,
Oleg Cmiljanić
,
Stergios A. Polyzos
,
Sanja Borozan
,
Emir Muzurović
,
Dimitri P. Mikhailidis